Preliminary Data From Groundbreaking Genome Editing Clinical Trial Encouraging
September 05, 2018
September 05, 2018
CHAPEL HILL, North Carolina, Sept. 5 -- The University of North Carolina School of Medicine issued the following news:
Preliminary safety and efficacy data from the first-ever trial studying an in vivo genome editing therapy have been presented by UNC's Joseph Muenzer, MD, PhD, at the 2018 Annual Symposium of the Society for the Study of Inborn Errors of Metabolism (SSIEM) this week in Athens, Greece.
Muenzer, a professor of pediatric genetics and metabolism at the UNC . . .
Preliminary safety and efficacy data from the first-ever trial studying an in vivo genome editing therapy have been presented by UNC's Joseph Muenzer, MD, PhD, at the 2018 Annual Symposium of the Society for the Study of Inborn Errors of Metabolism (SSIEM) this week in Athens, Greece.
Muenzer, a professor of pediatric genetics and metabolism at the UNC . . .